Akkermansia muciniphila: A key player in gut microbiota-based disease modulation

Abstract

Akkermansia muciniphila (A. muciniphila), a mucin-degrading bacterium residing in the gut’s mucus layer, has emerged as a key modulator of host physiology with significant implications for health and disease. Growing evidence shows that A. muciniphila influences host metabolism, strengthens gut barrier integrity, modulates microbial composition, and regulates immune responses. This review synthesizes current literature on A. muciniphila, emphasizing its role in conditions such as metabolic disorders, inflammatory bowel disease (IBD), Clostridioides difficile infection (CDI), cancer, cardiovascular disease, and aging. In metabolic disorders, A. muciniphila improves insulin sensitivity, reduces adiposity, and increases GLP-1 secretion through mechanisms involving short-chain fatty acid (SCFA) production and TLR2 activation. It also restores microbial balance and reduces inflammation in type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). In IBD, it enhances mucus secretion, tight junction integrity, regulatory T cell expansion, and suppresses pro-inflammatory cytokines. In CDI, it promotes epithelial protection and colonization resistance by enriching butyrate producers. In cancer, it boosts immune checkpoint inhibitor efficacy by enhancing IL-12 and T cell activation. It also reduces vascular inflammation and calcification in cardiovascular disease via propionate production. In aging, A. muciniphila improves metabolic health, reduces chronic inflammation, promotes SCFA production, and preserves blood–brain barrier integrity. Both live and pasteurized forms are effective, with pasteurized, particularly Amuc_1100, showing enhanced benefits. Broader application requires large-scale trials, better understanding of host and strain variability, and development of personalized, synergistic therapies.